LifeStance Health Group Stock Price, News & Analysis (NASDAQ:LFST)

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LifeStance Health Group in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LFST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LFST, but not buy additional shares or sell existing shares.
View LFST analyst ratings or view top-rated stocks.

4 brokerages have issued twelve-month price objectives for LifeStance Health Group's stock. Their LFST share price targets range from $8.00 to $9.00. On average, they expect the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for LFST or view top-rated stocks among Wall Street analysts.

LifeStance Health Group's stock was trading at $4.94 at the beginning of the year. Since then, LFST shares have increased by 35.4% and is now trading at $6.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our LFST earnings forecast.

LifeStance Health Group, Inc. (NASDAQ:LFST) released its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.10. The business had revenue of $262.90 million for the quarter, compared to the consensus estimate of $255.18 million. LifeStance Health Group had a negative net margin of 18.72% and a negative trailing twelve-month return on equity of 12.59%. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period last year, the company earned ($0.11) earnings per share.

ETFs with the largest weight of LifeStance Health Group (NASDAQ:LFST) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Global X Telemedicine & Digital Health ETF (EDOC) and First Trust Small Cap Growth AlphaDEX Fund (FYC).iShares U.S. Healthcare Providers ETF (IHF) and

LifeStance Health Group issued an update on its FY 2023 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.03 billion-$1.04 billion, compared to the consensus revenue estimate of $1.03 billion.

(LFST) raised $640 million in an initial public offering (IPO) on Thursday, June 10th 2021. The company issued 40,000,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies, TPG Capital BD LLC, UBS Investment Bank and William Blair served as the underwriters for the IPO and Capital One Securities, AmeriVet, Drexel Hamilton, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

LifeStance Health Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.44%), Brown Advisory Inc. (1.08%), Principal Financial Group Inc. (1.03%), Rock Springs Capital Management LP (0.97%), Jennison Associates LLC (0.54%) and Charles Schwab Investment Management Inc. (0.20%). Insiders that own company stock include Anisha Patel-Dunn, Ann Varanakis, Danish J Qureshi, Gwen H Booth, Jeffrey Crisan, Jesse Michael Bruff, Kenneth T Mills, Kevin Michael Mullins, Michael K Lester, Ryan Pardo, Silversmith Partners I Gp, Llc, Summit Partners Growth Equity and Warren Gouk.
View institutional ownership trends.

Shares of LFST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.